ArticleBMC infectious diseases2013
Therapy of intracellular Staphylococcus aureus by tigecyclin.
Article in BMC infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Research progress and future prospects of antibacterial drug-loaded bone cement in the treatment of orthopedic infections.Journal of orthopaedic surgery and research · 2026Review
- Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review.Infectious diseases and therapy · 2026Review
- Tigecycline Containing Polymethylmethacrylate Cement Against MRSA, VRE, and ESBL-In Vitro Mechanical and Microbiological Investigations.Antibiotics (Basel, Switzerland) · 2024Article
- Review
- Rifampicin restores extracellular organic matrix formation and mineralization of osteoblasts after intracellularBone & joint research · 2022Article
- In vitro antibiotic activity against intraosteoblastic Staphylococcus aureus: a narrative review of the literature.The Journal of antimicrobial chemotherapy · 2021Review
- Biomechanical comparison of tigecycline loaded bone cement with vancomycin and daptomycin loaded bone cements.Acta orthopaedica et traumatologica turcica · 2020Article
- In vitro antimicrobial susceptibility testing methods: agar dilution to 3D tissue-engineered models.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Review
- Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA.Clinical orthopaedics and related research · 2015Article
- Antimicrobial activity against intraosteoblastic Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2015Article
- Staphylococcus aureus vs. Osteoblast: Relationship and Consequences in Osteomyelitis.Frontiers in cellular and infection microbiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the fields of traumatology and orthopaedics staphylococci are the most frequently isolated pathogens. Staphylococcus aureus and Staphylococcus epidermidis are known to be the major causative agents of osteomyelitis. The increasing number of multiresistant Staphylococcus aureus and resistant coagulase-negative staphylococci as a trigger of complicated osteomyelitis and implant-associated infections is a major problem. Antibiotic therapy fails in 20% of cases. Therefore the development of novel antibiotics becomes necessary.
methodsThis study analyses tigecyclin, the first antibiotic of the glycylines, as a potential therapy for osteomyelitis caused by multiresistant Staphylococcus aureus. Therefore its intracellular activity and the potential use in polymethylmetacrylate-bone cement are examined. The intracellular activity of tigecyclin is determined by a human osteoblast infection model. The investigation of the biomechanical characteristics is conducted concerning the ISO 5833-guidelines.
resultsTigecyclin shows in vitro an intracellular activity that ranges between the antimicrobial activity of gentamicin and rifampicin. A significant negative effect on the biomechanical characteristics with an impaired stability is detected after adding tigecyclin to polymethylmetacrylate-bone cement with a percentage of 1.225% per weight.
conclusionsThis study shows that tigecyclin might be a potent alternative for the systemic therapy of osteomyelitis and implant-associated infections whereas the local application has to be reconsidered individually.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.